LIVN
LivaNova PLC
LIVN offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over LIVN overall, supported by stronger fundamentals and stronger modeled upside.
LIVN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
LIVN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LIVN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $90.20 | — |
| Cheap | 29x | $87.18 | -3.3% |
| Current | 30x | $90.20 | — |
| Fair | 112x | $337 | +274% |
| Expensive | 769x | $2,314 | +2465% |
Historical ranges are pointers, not guarantees.
LIVN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LIVN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LIVN, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over LIVN on the outlook, with more favorable profitability expectations.
LIVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.53 | +50% |
| Q3 2026 | $3.01 | +$6.99 |
| Q2 2026 | $3.39 | +$7.26 |
| Q1 2026 | $1.96 | +$6.03 |
| Q4 2025 | -$4.45 | -484% |
| Q3 2025 | -$3.98 | -1048% |
| Q2 2025 | -$3.87 | -$3.55 |
| Q1 2025 | -$4.07 | -$3.47 |
| Q4 2024 | $1.16 | +262% |
LIVN has returned to profit: it earned $3.01 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LIVN on earnings, with more consistent year-over-year improvement.
LIVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $393.1M | +9.9% |
| Q2 2026 | $390.6M | +11% |
| Q1 2026 | $362.3M | +14% |
| Q4 2025 | $360.9M | +12% |
| Q3 2025 | $357.8M | +12% |
| Q2 2025 | $352.5M | +11% |
| Q1 2025 | $316.9M | +7.4% |
| Q4 2024 | $321.8M | +3.8% |
LIVN's revenue has grown year over year for 16 quarters in a row: $393M last quarter, up 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | -7.9 points |
| Q2 2026 | 13% | -2.7 points |
| Q1 2026 | 11% | -3.9 points |
| Q4 2025 | 12% | +0.3 points |
| Q3 2025 | 15% | +3.9 points |
| Q2 2025 | 15% | +2.8 points |
| Q1 2025 | 15% | +9.8 points |
| Q4 2024 | 12% | +40 points |
LIVN's operating margin was 7.2% last quarter, down 7.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LIVN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LIVN on profitability, with a higher operating margin.
LIVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $42.9M | -31% |
| Q2 2026 | $35M | -27% |
| Q1 2026 | $926K | -93% |
| Q4 2025 | $50.2M | -27% |
| Q3 2025 | $62.2M | +89% |
| Q2 2025 | $47.8M | +53% |
| Q1 2025 | $13.2M | +268% |
| Q4 2024 | $68.3M | +66% |
LIVN still generates free cash flow, though less than at its 2024 peak: $129M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LIVN on cash flow, with more consistent year-over-year improvement.
LIVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +1.1M shares |
| 1 year | +4% | +2.2M shares |
| 3 years | +6.3% | +3.4M shares |
| 5 years | +11% | +5.8M shares |
| Available history | +19% | +9M shares |
LIVN has 57M diluted shares, up 4% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LIVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LIVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.6x | Net Cash |
| Q4 2024 | 1.3x | Healthy |
LIVN has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LIVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.0 | Neutral |
| Stochastic | 56.1 | Neutral |
LIVN's weekly RSI is 67 (neutral) and its Stochastic is 56 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LIVN PE vs Healthcare Sector
| Metric | LIVN | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 16% above |
| PE % | 19 | 29 | 10 pts below |
LIVN has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LIVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 12% above |
| 20 week MA | $80.3 | 12% above |
| 50 week MA | $72.3 | 25% above |
| 100 week MA | $59.7 | 51% above |
| 200 week MA | $55.5 | 62% above |
LIVN is in an uptrend: it's above all five of its weekly moving averages, and 62% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
LIVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $75.4 | $67.4 | -11% |
| 2021 | $67.4 | $85.2 | +26% |
| 2022 | $85.2 | $53.7 | -37% |
| 2023 | $53.7 | $51.7 | -3.6% |
| 2024 | $51.7 | $46.6 | -10% |
| 2025 | $46.6 | $62.9 | +35% |
| 2026 YTD | $62.9 | $90.2 | +43% |
LIVN has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.